News
News
12
August
2025
Primo Biotechnology and Anbogen Therapeutics Forge Strategic Collaboration to Co-Develop Precision Radioligand for Solid Tumors Diagnosis and Therapy
5
August
2025
Primo Biotechnology and Terthera B.V. Announce Strategic Partnership to Advance Terbium-161 Radioligand Therapies in Taiwan
2
JuLy
2025
Primo Biotechnology Secures A Funding and Targets 2026 IPO to Strengthen Global Radiopharmaceutical Strategy
24
April
2025
Primo’s Taoyuan Facility Achieves PIC/S GMP Certification, Paving the Way for Global Expansion in Nuclear Medicine.
19
March
2025
Primo Partners with ABX to Bring PB01 Closer to Taiwan’s Prostate Cancer Market
9
January
2025
Primo Biotechnology Partners with Antelope Surgical Solutions for World’s First FDA-Approved Phase I/II Trial of AS1986NS
13
January
2025
Primo Partners with SHINE to Advance Precision Cancer Care in Asia-Pacific
17
November
2023
Primo wins 2023 TAIPEI Prominent Enterprise Award
21
July
2023
Primo Biotechnology Raises Over 6.5 Million USD in Funding, Pioneering an International-level Radiopharmaceutical Manufacturing Facility
1
July
2022
Dr. Chi-Wei Chang joins Primo as CTO of Radiopharmaceutical Chemistry.
1
May
2022
Tackle Cancer Challenge
18
NOV
2021
Are Asian Countries Ready for Novel Radiopharmaceuticals?
15
NOV
2021